Further experiments validated that PI3K-AKT inhibitor buparlisib (BKM120) could synergize with trastuzumab, resulting in an enhanced anti-tumor effect, and provided a promising therapeutic strategy for HER2-positive GC patients. This evidence concerns the gene AKT1 and gastric cancer.